Pharmacokinetics, pharmacodynamics, and safety of the novel CXCR3 antagonist ACT-777991: Results from the first-in-human study in healthy adults.
Marie-Laure BoofMartine GéhinChristine Voors-PetteChih-Hsuan HsinVirginie SippelDaniel S StrasserJasper DingemansePublished in: British journal of clinical pharmacology (2023)
In this first-in-human study, ACT-777991 showed good tolerability for all doses tested and a PK and TE profile suitable for further clinical development.